Notes
The study was supported by Teva Pharmaceuticals Limited.
no asthma-related hospital attendance; no acute oral corticosteroid prescription ; no lower respiratory tract infection requiring antibiotics; no respiratory-related hospital admission or emergency-department attendance; and limited albuterol use (≤ 2 puffs/day)
Reference
Colice G, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. Journal of Allergy and Clinical Immunology : 13 Apr 2013. Available from: URL: http://dx.doi.org/10.1016/j.jaci.2013.02.008
Rights and permissions
About this article
Cite this article
HFA-beclomethasone good option for asthma at lower cost. PharmacoEcon Outcomes News 678, 10 (2013). https://doi.org/10.1007/s40274-013-0408-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0408-4